ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Rhea-AI Summary

ADAR1 Capital Management, the largest shareholder of Keros Therapeutics (NASDAQ: KROS) with a 13.3% stake, has released an investor presentation detailing its reasons for opposing the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the company's Board of Directors. The decision will be voted on at Keros' Annual Meeting of Stockholders scheduled for June 4, 2025.

AUSTIN, Texas, May 12, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an investor presentation outlining its rationale for withholding votes on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Keros Board of Directors at the Company's upcoming Annual Meeting of Stockholders, scheduled for June 4, 2025.

The presentation can be viewed here.

About ADAR1 Capital Management

ADAR1 Capital Management is an SEC-registered investment manager based in Austin, Texas, focused on public and private equity investments in the life sciences and biotechnology sectors. The firm was founded in October 2018 by Dr. Daniel Schneeberger, who brings over 20 years of experience spanning scientific research, healthcare consulting, institutional investing, and executive leadership in the healthcare industry. He is supported by a team of experienced professionals with deep medical and scientific expertise and a strong track record of biopharmaceutical investing.

Forward-Looking Statements

Certain financial projections and statements made in this press release and accompanying letter have been derived or obtained from filings made with the Securities and Exchange Commission ("SEC") or other regulatory authorities and from other third-party reports. Neither ADAR1 nor any of its affiliates shall be responsible or have any liability for any misinformation contained in any third-party SEC or other regulatory filing or third-party report. Select figures presented in this press release and accompanying letter have not been calculated using generally accepted accounting principles ("GAAP") and have not been audited by independent accountants. Such figures may vary from GAAP accounting in material respects and there can be no assurance that the unrealized values reflected within such materials will be realized. Nothing in this press release and accompanying letter is intended to be a prediction of the future trading price or market value of securities of the Company. Words such as "anticipate", "believe", "could", "estimate", "expect", "may", "ought to", "plan", "project", "seek", "should", "will", "would" and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Reliance on any forward-looking statements involves known and unknown risks and uncertainties and there is no assurance or guarantee that actual results or performance of the Company will not differ, and such differences may be material.  In addition, there can be no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. The estimates, projections and potential impact of the opportunities identified by ADAR1 herein are based on assumptions that ADAR1 believes to be reasonable as of the date of this press release.

Contact:
info@adar1.com
512-254-3790

View original content to download multimedia:https://www.prnewswire.com/news-releases/adar1-capital-management-releases-investor-presentation-outlining-its-rationale-for-withholding-votes-from-directors-dr-mary-ann-gray-and-dr-alpna-seth-302452575.html

SOURCE ADAR1 Capital Management LLC

FAQ

Why is ADAR1 Capital Management opposing Keros Therapeutics (KROS) board members?

ADAR1 Capital Management, which owns 13.3% of Keros Therapeutics, has released an investor presentation explaining their rationale for withholding votes from directors Dr. Mary Ann Gray and Dr. Alpna Seth at the upcoming June 4, 2025 stockholder meeting.

What percentage of Keros Therapeutics (KROS) does ADAR1 Capital Management own?

ADAR1 Capital Management owns approximately 13.3% of Keros Therapeutics' outstanding shares, making it the company's largest stockholder.

When is Keros Therapeutics (KROS) 2025 Annual Meeting of Stockholders?

Keros Therapeutics' Annual Meeting of Stockholders is scheduled for June 4, 2025.

Which Keros Therapeutics (KROS) board members are facing opposition from ADAR1?

Dr. Mary Ann Gray and Dr. Alpna Seth are the board members facing opposition from ADAR1 Capital Management for their re-election to the Keros Board of Directors.